Cell News and Research

RSS

Caris Life Sciences presents new diagnostic data at ACG 2010

Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic technologies, today announced upcoming highlights from the Company's presentations at the 2010 Annual Meeting of the American College of Gastroenterology ("ACG 2010") held in San Antonio, TX, October 15-20. In total, Caris was awarded 17 accepted abstracts, three of which are ACG Presidential Poster Award recipients.

15 Oct 2010

Octapharma USA accepts applications for 25th Anniversary Grants Program

Octapharma USA is accepting applications for the Octapharma 25th Anniversary Grants Program, which supports clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immune therapy, intensive care and emergency medicine. The application deadline is April 1, 2011.

15 Oct 2010

New insights into HIV infection process may allow antiviral drug development

New insights into the human immunodeficiency virus (HIV) infection process, which leads to acquired immunodeficiency syndrome (AIDS), may now be possible through a research method recently developed in part at the National Institute of Standards and Technology (NIST), where scientists have glimpsed an important protein molecule's behavior with unprecedented clarity.

15 Oct 2010

Researchers develop new lab test for diagnosing preeclampsia

In as many as 8 percent of pregnancies worldwide, women who seem fine for months develop preeclampsia, a serious complication causing symptoms including high blood pressure, severe swelling, and problems with placental development. The untreatable and unpredictable condition, with no known cause, often requires premature delivery, and can sometimes kill the mother and the fetus.

15 Oct 2010

Scientists discover mechanism of anticancer drug to kill cancer cells

A potent drug derived from an evergreen tree may soon save the lives of some patients with the deadliest form of breast cancer. According to the National Cancer Institute, breast cancer will claim approximately 40,000 lives in the U.S. this year.

15 Oct 2010

Applied Skin Technology launches three revolutionary products for skin damage

Applied Skin Technology announces the launch of three breakthrough moisturizers, harnessing cutting-edge skin care technology, and using the most effective skin restoring ingredients available. These revolutionary products are formulated for three different categories: women, men, and a recovery cream for skin that has been damaged due to a medical condition or the side effect of medical treatment.

15 Oct 2010

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

FibroGen, Inc. today announced initiation of a phase 2 study to compare the efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), with placebo in reversing liver fibrosis (scarring of the liver) due to chronic infection with hepatitis B virus (HBV).

15 Oct 2010

ACS awards Research Scholar Grant to Rensselaer researcher for breast cancer study

A recent Research Scholar Grant from the American Cancer Society acknowledges the potential of Rensselaer researcher Lee Ligon's work on breast cancer. Ligon is investigating interactions between cells as breast cancer spreads within the body.

15 Oct 2010

New, affordable technology for cervical cancer screening

Current cervical cancer screening is time consuming and expensive, but now new breakthrough technology developed by European researchers should allow large-range screening by non-medical personnel with almost immediate results and at a much lower cost.

15 Oct 2010

ARTS protein increases apoptosis mechanism to balance stem cells' regenerative power: Research

Stem cells, the prodigious precursors of all the tissues in our body, can make almost anything, given the right circumstances. Including, unfortunately, cancer. Now research from Rockefeller University shows that having too many stem cells, or stem cells that live for too long, can increase the odds of developing cancer.

15 Oct 2010

Scientists identify mechanism that regulate nuclear size

Size matters when it comes to the nucleus of a cell, and now scientists have discovered the signals that control how big the nucleus gets. Nuclear size varies not only among different species, but also in different types of cells in the same species and at different times during development. In addition, cancer cells are known to develop larger nuclei as they become more malignant. Screening for cervical cancer, for example, involves looking for grossly distorted nuclei in cervical cells collected during a Pap smear.

15 Oct 2010

Moores Cancer Center files IND application for topical NexACT-based formulation

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Moores Cancer Center at the University of California San Diego (UCSD) has filed an Investigational New Drug Application with the U.S. Food & Drug Administration ("FDA") for approval to test Nupen, Apricus Bio's proprietary, topical NexACT-based formulation of filgrastim (Neupogen).

15 Oct 2010

Prolong Pharmaceuticals receives $30 million from private investor group

Prolong Pharmaceuticals today announced that the company has received a commitment of $30 million in funding from a private investor group. The monies will be dedicated to the company's continuing research and development efforts and clinical programs targeting anemias resulting from oxygen deficiency.

15 Oct 2010

FDA approves Gamunex-C for primary immunodeficiency treatment

Talecris Biotherapeutics announced today that the U.S. Food and Drug Administration (FDA) approved Gamunex-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency (PI).

15 Oct 2010

Study finds multiple genetic variations can contribute to common childhood obesity

A new study uncovers multiple genetic variations associated with common childhood obesity. The research, published by Cell Press on October 14th in the American Journal of Human Genetics, is likely to guide future studies aimed at characterizing the affected genes and unraveling the complex biology that underlies childhood obesity.

15 Oct 2010

Omeros receives additional NIDA grant for clinical studies in Addiction program

Omeros Corporation today announced that the National Institute on Drug Abuse (NIDA) has provided an additional grant to fund clinical studies for the Company's Addiction program. This grant, which is for a total of approximately $3.6 million to be paid over a four-year period in equal amounts, will fund direct and indirect costs of Phase 2 clinical studies to be conducted by researchers at the New York State Psychiatric Institute.

14 Oct 2010

IMD receives EPO patent for NADiA ultra-sensitive protein detection and cell phenotyping platform

IRIS International, Inc. a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, today announced that Iris Molecular Diagnostics (IMD)has been granted Patent No. EP1842226B1 by the European Patent Office (EPO) covering aspects of IMD's NADiA ultra-sensitive protein detection and cell phenotyping platform, which can detect proteins in the femtogram (1 quadrillionth) per milliter range and phenotype single cells.

14 Oct 2010

Scientists discover 'switch' mechanism of lymphatic and blood vessel cells

Scientists at the University of East Anglia have made an important breakthrough in the way anti-cancer drugs are tested. A tumour cannot grow to a large size or spread until it has developed its own blood supply and leading research has looked for a way of halting capillary formation to stop tumours taking hold.But new findings published today in the Journal of Cell Science have shown that scientists testing such treatments may not have been studying exactly what they thought they were.

14 Oct 2010

Childrens Hospital Los Angeles receives $1M NCI grant for eye port clinical trial to treat retinoblastoma in children

The Vision Center at Childrens Hospital Los Angeles has been awarded a $1 million grant from the National Cancer Institute (NCI) to conduct a clinical trial on a new drug delivery system to treat young children diagnosed with retinoblastoma. The device is designed to deliver chemotherapy through a tiny silicone cup sealed to the outer surface (sclera) of the eye, which can more directly target cancer cells and greatly reduce the side effects caused by current chemotherapy treatments.

14 Oct 2010

Scientists identify protein in urine can indicate prostate cancer risk

Cancer research UK scientists have shown that a protein in urine could be a powerful indicator of prostate cancer risk, according to a study published in PLoS ONE.

14 Oct 2010